← SynDRA
AZD3965
SynDRA canonical compound SYN0038095 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | SLC16A1 | SLC16A7 |
|---|
| Mechanism of action | monocarboxylate transporter inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- monocarboxylate transporter inhibitor
Cross-references
Synonyms
- AZD-3965
- Azd-3965
- RefChem:116042
- MCT1 Inhibitor AZD3965
- Monocarboxylate Transporter 1 Inhibitor AZD3965
- AZD 3965 [WHO-DD]
- MFCD28963899
- UNII-39OM5Y4K2F
- orb1304420
- SCHEMBL2875156
- C21H24F3N5O5S
- SCHEMBL29127799
- GTPL10605
- EX-A806
- GLXC-90495
- HMS3873L03
- NSC787047
- s7339
- AKOS027323783
- CCG-269813
- EBC-521431
- NSC-787047
- NCGC00415059-01
- AC-33040
- AS-75322
- BA164976
- HY-12750
- F865682
- BRD-K25210703-001-01-9
- (S)-5-(4-Hydroxy-4-methylisoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-((5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
Look up AZD3965 in the interactive SynDRA portal →